Evidence map›Paper›PMID 22345475›Full record

ArticleJournal of virology2012

Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions.

Jérôme Bouchet, Cécile Hérate, Carolin A Guenzel, Christel Vérollet, Annika Järviluoma, Julie Mazzolini, Salomeh Rafie, Patrick Chames, Daniel Baty, Kalle Saksela and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Single domain antibodies for the knockdown of cytosolic and nuclear proteins.Protein science : a publication of the Protein Society · 2017
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Small molecule inhibitors of the HIV-1 virulence factor, Nef.Drug discovery today. Technologies · 2013
    Review
  15. SH3 domains come of age.FEBS letters · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Jérôme BouchetInstitut Cochin, CNRS (UMR8104), Université Paris Descartes, Paris, France.
Cécile Hérate
Carolin A Guenzel
Christel Vérollet
Annika Järviluoma
Julie Mazzolini
Salomeh Rafie
Patrick Chames
Daniel Baty
Kalle Saksela
Florence Niedergang
Isabelle Maridonneau-Parini
Serge Benichou
Inserm · FRUniversité Paris Cité · FRInstitut Cochin · FRHelsinki University Hospital · FIInstitut de Pharmacologie et de Biologie Structurale · FRUniversité Toulouse III - Paul Sabatier · FRUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-1 Nef is essential for AIDS pathogenesis, but this viral protein is not targeted by antiviral strategies. The functions of Nef are largely related to perturbations of intracellular trafficking and signaling pathways through leucine-based and polyproline motifs that are required for interactions with clathrin-associated adaptor protein complexes and SH3 domain-containing proteins, such as the phagocyte-specific kinase Hck. We previously described a single-domain antibody (sdAb) targeting Nef and inhibiting many, but not all, of its biological activities. We now report a further development of this anti-Nef strategy through the demonstration of the remarkable inhibitory activity of artificial Nef ligands, called Neffins, comprised of the anti-Nef sdAb fused to modified SH3 domains. The Neffins inhibited all key activities of Nef, including Nef-mediated CD4 and major histocompatibility complex class I (MHC-I) cell surface downregulation and enhancement of virus infectivity. When expressed in T lymphocytes, Neffins specifically inhibited the Nef-induced mislocalization of the Lck kinase, which contributes to the alteration of the formation of the immunological synapse. In macrophages, Neffins inhibited the Nef-induced formation of multinucleated giant cells and podosome rosettes, and it counteracted the inhibitory activity of Nef on phagocytosis. Since we show here that these effects of Nef on macrophage and T cell functions were both dependent on the leucine-based and polyproline motifs, we confirmed that Neffins disrupted interactions of Nef with both AP complexes and Hck. These results demonstrate that it is possible to inhibit all functions of Nef, both in T lymphocytes and macrophages, with a single ligand that represents an efficient tool to develop new antiviral strategies targeting Nef.

Indexed as

Amino Acid SequenceAntiviral AgentsCD4 AntigensCell LineDown-RegulationGene OrderHistocompatibility Antigens Class IHIV-1HumansLymphocyte Specific Protein Tyrosine Kinase p56(lck)MacrophagesMolecular Sequence Datanef Gene Products, Human Immunodeficiency VirusPhagocytosisProtein BindingProtein TransportAntiviral AgentsCD4 AntigensHistocompatibility Antigens Class ILymphocyte Specific Protein Tyrosine Kinase p56(lck)nef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1Proto-Oncogene Proteins c-hckRecombinant Fusion ProteinsSingle-Chain AntibodiesTranscription Factor AP-1

Identifiers

PMID22345475
PMCPMC3347381
OpenAlexW2168429597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.